Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Invited discussant abstract 315O

Date

18 Dec 2015

Session

Head and neck cancer

Presenters

Brigette B Ma

Authors

B.B. Ma

Author affiliations

Department Of Clinical Oncology, Prince of Wales Hospital, Hong Kong/CN

More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Login

View the abstract discussed:

Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study

Resources from the same session

18 Dec 2015

Second-line afatinib vs methotrexate (MTX) in patients (pts) with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC): subgroup/biomarker analysis of LUX-head and neck 1 (LUX-H&N1)

Presenter: Makoto Tahara

Session: Head and neck cancer

Resources:

Abstract

Presentation

Webcast

18 Dec 2015

Invited discussant abstract 314O

Presenter: Fortunato Ciardiello

Session: Head and neck cancer

Resources:

Webcast

18 Dec 2015

Early or delayed use of TKI

Presenter: Makoto Tahara

Session: Head and neck cancer

Resources:

Presentation

Webcast

18 Dec 2015

Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study

Presenter: Chiun Hsu

Session: Head and neck cancer

Resources:

Abstract

Presentation

Webcast